AbbVie ABBV is set to report third-quarter earnings on Oct. 30, before the opening bell. The Zacks Consensus Estimate for ...

AbbVie ABBV announced that the FDA approved its lymphoma drug Epkinly (epcoritamab) for a second indication — follicular ...

Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult ...

However, on October 11, the CME FedWatch tool showed that 89.5% of the market now expects a 25 bps rate cut and the rest ...

In that indication, the drug competes with AbbVie and Genmab’s rival CD20xCD3 bispecific Epkinly (epcoritamab), so moving it into the first relapse setting could hand Roche an advantage.

AbbVie (NYSE: ABBV) today announced that nine provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...

Genmab GMAB over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes ...

This new Roche drug will compete against Epkinly, AbbVie’s recently approved DLBCL drug. Roche’s Polivy is now approved as an earlier line of treatment for patients who have diffuse large B ...

Bogart Wealth LLC cut its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 2.2% during the 3rd quarter, according ...

Argent Capital Management LLC reduced its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 96.3% in the 3rd quarter, ...

AbbVie (NYSE: ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Genmab (GMAB – Research Report) and keeping the price target at ...